In their guidelines, Campbell et al. have tried to make physicians aware of the overuse of RN, especially for small renal lesions that are eligible for other treatment modalities.

No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.